Advancing drug repositioning and development for alzheimer's disease using functional genomics and computational phenomics

Ended Project Grant Awarded Last action

Award ID
R56AG068026
Recipient
Awarding agency
Obligated
$3,734,179

Award facts

Assistance listing
93.866 Aging Research
Completion date
Originally
Funding
  • $2,978,197.71 Federal
  • $755,981.00 Non-federal
Place of performance
Nashville, TN 37203, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Alzheimer's disease (ad) is a heterogeneous neurodegenerative disorder which is highly prevalent in the global population, affecting around 46 million individuals. Due to increased longevity, the prevalence is rising. Ad is characterized pathophysiologically by extracellular SS- amyloid deposition and intracellular hyperphosphorylated TAU. Current medications for ad provide some relief from disease symptoms but are not effective in all patients while severe side effects are observed. The disease is highly heritable and has a complex molecular basis, with a substantial polygenic component. There is an urgent need for developing approaches to target discovery and drug repurposing. The combination of methodological analytic advances, functional genomics data, and phenotype-rich datasets can be the foundation for identifying new therapies. Our central hypothesis is that an integrative approach spanning human phenomics and genomics will offer new ad therapeutic possibilities, including drug repositioning, and provide a powerful approach to drug target discovery. We will develop cutting-edge genetics-anchored computational methodologies for ad drug repurposing, generate a community resource to advance research in ad therapeutics development, leverage a collaboration (infrastructure and machine learning) with google, and conduct target validation in a zebrafish model of ad. We have engaged an interdisciplinary team to ensure the success and broad impact of our proposal and lay the groundwork for future innovative research.

Transactions

Action Federal Non-federal Date
Amendment -$1,698 $0
Amendment $733,967 $0
Amendment $733,967 $0
Amendment $0 $0
Amendment $0 $0
Amendment $755,981 $0
Original award $755,981 $755,981

Subawards

Subrecipient Amount Awarded
The Council Of The Queensland Institute Of Medical Research Advancing drug repositioning and development for Alzheimer's Disease using functional genomics and computational phenomics $69,801

Quick answers

Who received award R56AG068026?

R56AG068026 was awarded to Vanderbilt University Medical Center by National Institute on Aging (National Institutes of Health) on September 5, 2021.

How much is award R56AG068026 worth?

$3,734,179 has been obligated on R56AG068026: $2,978,198 in federal funding and $755,981 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login